Are you a student, postdoc, or PI?
Do you want to learn more about business in life sciences?
We have the pleasure to invite you to the first Business Journal Club organised by the EPFL Business Club-Healthcare, supported by the AIM (Applied Innovation Mechanism) at VPI, the BioScience Network Lausanne (BSNL) and the School of Life Sciences.
The event will take place on Wednesday May 10th in room AI.1.153 from 17:00 to 19:00.
1) create a space of proactive exchange among scientists, in the form of an EPFL “Business Laboratory”,
2) working with real internal projects and with success, and especially failure, examples, we aspire to cultivate an applied innovation and technology transfer oriented culture,
3) accompany and support, when possible, basic internal research with the know how, expertise, and network necessary, to facilitate “turning science into products” to serve society.
Main activities of the Business Club:
· Business Journal Club
· Business Case/Plan Study Development with EPFL real projects
· R&D expertise networking
· Transformational Innovation Ideas and initiatives
Some operational characteristics of the Business Club:
· Executive committee (renewable every semester)
· Industrial advisory committee
· Members register (no fees but via application and invitation)
· Strict confidentiality
Our Business Journal Club:
It is a fact: the vast majority of Start Ups is doomed to fail.
Rarely we discuss about failures.
We, thus, believe, that more than continuously discussing the same rare success stories, understanding failures has lot to teach us.
Our Business Club decided to preferably discuss the reasons why companies and technologies fail in their path to market.
We hope, thus, to promote a cultural change to start thinking of failures as important experiences, lessons and assets towards success.
Our 1st Case Study:
In this first Business Case Study session we will discuss about the rise and fall of Theranos company and its CEO and founder Elizabeth Holmes, whom was named by Forbes the youngest self-made female billionaire in the world due to a $9 billion valuation of Theranos. President Obama had named Elizabeth Holmes global ambassador for US entrepreneurship.
A year later Forbes revised her net value “From $4.5 Billion to Nothing”.
We shall try to analyse with you (to the extent possible), all aspects of this case, ranging from the Business Model, to the Intellectual property to the R&D strategy and product regulatory and clinical liabilities, down to the responsibilities of Investors, Authorities and Media.